Trial reportBMC anesthesiology2026
Reduced-exposure neuromuscular blockade strategies for total laparoscopic hysterectomy within an ERAS pathway: a randomized controlled trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundNeuromuscular blocking agents (NMBAs) facilitate tracheal intubation and laparoscopic exposure, but residual neuromuscular blockade remains a perioperative concern. We evaluated whether reducing NMBA exposure during total laparoscopic hysterectomy within an Enhanced Recovery After Surgery (ERAS) pathway maintained airway and operative conditions while limiting interpretation of postoperative neuromuscular outcomes to the available measurements.
methodsIn this single-center, randomized, patient-, surgeon-, postoperative assessor-, and statistician-blinded, parallel-group trial, 135 patients scheduled for elective total laparoscopic hysterectomy were allocated 1:1:1 to no muscle relaxant (NM), rocuronium for induction only (MI), or rocuronium for induction plus maintenance (MIC). After post-randomization exclusions, 130 patients were included in the modified intention-to-treat cohort. The primary endpoint was the proportion of patients achieving clinically acceptable intubating conditions, defined as excellent or good Cooper grades; the full Cooper grade distribution was reported as a supportive outcome. Surgical workspace quality, Cormack-Lehane grades, extubation time, and recovery measures were secondary or supportive outcomes, whereas pain scores and inflammatory biomarkers were analyzed as exploratory outcomes.
resultsSuccessful tracheal intubation was achieved in all analyzed patients. Clinically acceptable intubating conditions were observed in 43/45 patients (95.6%; 95% CI, 84.9%-99.5%) in the NM group, 43/43 patients (100.0%; 95% CI, 91.8%-100.0%) in the MI group, and 42/42 patients (100.0%; 95% CI, 91.6%-100.0%) in the MIC group, with no statistically significant between-group differences observed. No statistically significant between-group differences were observed in Cormack-Lehane grades, surgical workspace scores, extubation time, PACU stay, or hospital stay. In exploratory analyses, VAS pain scores at 2 and 4 h and immediate postoperative IL-6 concentrations were higher in the MIC group than in the other groups; a between-group difference was also observed for immediate postoperative TNF-alpha, with the highest mean value in the MI group. No chest-wall rigidity, difficult mask ventilation, failed intubation, or rescue NMBA administration for intubation difficulty occurred, and recorded adverse events were mainly postoperative nausea and vomiting.
conclusionIn this study, reduced NMBA exposure was not associated with differences in clinically acceptable intubating conditions, surgical workspace quality, or early recovery outcomes among selected patients undergoing elective total laparoscopic hysterectomy within an ERAS pathway. These findings suggest that reducing NMBA exposure may be feasible under carefully standardized anesthetic conditions. Further prospective studies incorporating quantitative neuromuscular monitoring are warranted to validate these findings.
trial registrationThe study was registered at the Chinese Clinical Trial Registry ( http://www.chictr.org.cn ) with the number ChiCTR2400080065 on January 19, 2024, after project approval in July 2021, ethics approval before enrollment in September 2022, and completion of the study period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.